Eloxx doses first patients in mid-stage Alport syndrome trial

Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4A5 genes and includes a randomized, placebo-controlled delayed-start design.

The initial assessment runs for 16 weeks and includes kidney-biopsy measures, with additional follow-up extending to 32 weeks. Initial results are expected around the middle of 2027 and final results later that year. Starting dosing is a development milestone, not evidence that the drug has demonstrated efficacy. The announcement contains no new treatment-response results and does not establish regulatory approval or a commercial launch date.

Sources:

• Eloxx Pharmaceuticals — first-patient announcement, PR Newswire